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Monoclonal antibody (MAb) lG12 binds the uncleaved HIV-l Gag polypeptide @55), but fails to recognize the final products of the proteolytic 
processing [Sarubbi, E. et al. (1991) FEBS Lett. 279,265269]. In this report we show that binding of MAb lG12 to a 1 lo-residue Gag fragment 
containing the p17-p24 cleavage site prevents proteolysis of this site by the HIV-l protease. Competition studies with synthetic peptides have been 
performed to map the binding site of MAb lG12 on Gag. The antibody recognizes a sequential epitope that spans the HIV-l protease cleavage 
site; determinants located on both p17 and p24 are required for antibody binding. MAb lG12 is also shown to lack any cross-reactivity with other 
HIV-l protease cleavage sites. 
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1. INTRODUCTION 
In the life cycle of the human immunodeficiency virus 
(HIV) the polypeptidic precursors endoded by the gag, 
pol and env genes are processed by proteolytic cleavage 
to yield the mature forms of structural proteins and 
enzymes [141. Even though the products of the pol and 
env genes have thus far attracted most interest as targets 
for anti-AIDS therapy [5], several groups have focused 
their attention on the Gag polypeptide. This protein is 
interesting not only for its ability to form virus-like 
particles when expressed in different host cells [6-111, 
but also for the recently reported possibility to use it as 
a target in a new approach to the chemotherapy of 
AIDS [12]. For these reasons the mechanism and the 
cellular compartments in which the virally-encoded 
aspartic protease (HIV-l protease) processes the Gag 
polypeptide are the subject of extensive investigation 
[13-l 71. Any specific reagent hat might be used in these 
studies to discriminate between unprocessed and proc- 
essed proteins would be extremely interesting. 
HIV-l Gag were fused to E. coli /%galactosidase. This 
Gag portion contains the p17-p24 cleavage site which 
is recognized and efficiently cleaved by the HIV-l pro- 
tease. After this treatment, however, the fusion protein 
is not bound by MA\> 1 G12 any longer [ 181. These data 
suggest hat MAb lG12 recognizes either a conforma- 
tional epitope destroyed upon cleavage by HIV-l pro- 
tease or a contiguous sequence ncompassing the p17- 
p24 cleavage site. 
In this study, MAb lG12 is shown to prevent the 
HIV-l protease-mediated cleavage of the p17-p24 site 
on the Gag precursor. Besides, competition studies with 
synthetic peptides show that the inhibition of proteo- 
lytic cleavage is not due to sterical hindrance, but to 
overlapping between the antibody epitope and the 
cleavage site. Similar experiments also provide indica- 
tions about the specificity of this interaction. 
2. MATERIALS AND METHODS 
2.1. Proteins and peptides 
In a Western Blot analysis of a total HIV-l lysate, 
monoclonal antibody lG12 (MAb lG12) immunostains 
the whole Gag precursor (~59, but fails to bind the 
Gag-derived mature proteins [I 81. Also, MAb 1G12 
binds the Gag fragment contained in Gal-gagl10, a 
protein fusion in which 110 amino acid residues from 
Recombinant HIV-l protease and Gal-gag110 fusion protein were 
expressed in E. coli, as previously described [18]. MAb lG12 was 
produced using Gal-gag110 for immunization and screening, as de- 
scribed [18]. All the peptides used in the competition studies were 
synthesized and purified by Chiron Mimotopes (Clayton, Australia). 
2.2. HIV-I protease assays 
*Corresponding author. Fax: (39) (2) 9647 4365. 
Abbreviations: HIV-l, human immunodeficiency virus type 1; AIDS, 
acquired immunodeficiency syndrome; ELISA, enzyme-linked im- 
munosorbent assay; BSA, bovine serum albumin; PBS, phosphate- 
buffered saline; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis. 
For the ELISA-like assay shown in Fig. 1, microtiter wells were 
coated overnight with 50 pl of MAb 1G12 or anti-B-galactosidase 
monoclonal antibody @omega), both as 20 pg/ml in PBS (50 mM 
sodium phosphate, pH 7.3, 150 mM sodium chloride). Unreacted sites 
were blocked with 200 ~1 of 3% bovine serum albumin (BSA) in PBS 
for 1 h. After washing with PBS, 50 ~1 of 100 ,ug/ml Gal-gag1 0 fusion 
protein were added and plates were incubated for 2 h at room temper- 
ature. Unbound protein was then discarded and plates were washed 
with PBS. 50 ~1 of different concentrations of HIV-l protease in PBS 
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containing 0.3% BSA were added to each well and plates were incu- 
bated for 1 h at room temperature. After washing with PBS, the 
amount of immobilized and uncleaved Gal-gag1 0 was determined by 
adding an anti-p24 polyclonal antibody (I:100 dil.) made in sheep 
(Biochrom, Germany) and then a peroxidase-labelled anti-sheep sec- 
ondary antibody (Dakopatts). 1 mg/ml o-phenyl-diamine (OPD) was 
used for the chromogenic reaction. 
For the Western blot analysis of Fig. 2, 100 ,@ml of Gal-gag1 0 
were incubated with different concentrations of MAb lG12 or anti-p- 
galactosidase monoclonal antibody (Promega) in PBS for 1 h at room 
temperature. HIV-l protease was added at a final concentration of 0.5 
,@ml and samples were incubated for 30 min at 37°C. SDS-PAGE 
loading buffer was added and samples were boiled for 5 min. Gel 
electrophoresis n a 7.5% acrylamide homogeneous gel and blotting 
on nitrocellulose were performed using a PhastSystem apparatus 
(Pharmacia) according to the manufacturer’s instructions. Nitrocellu- 
lose filters were blocked with 3% BSA and then incubated for 2 h with 
the anti-/?-galactosidase monoclonal antibody (2 @ml) followed by 
anti-mouse AuroProbeEM (Amersham) and IntenseBL silver en- 
hancement (Janssen). 
2.3. Competition assays 
60 ~1 of different peptide concentrations in PBS containing 0.3% 
BSA and 2.5% DMSO were added to MAb lGl2-coated microtiter 
wells (coating, blocking and washing were performed as for the 
ELISA). After 10 min 15 yl of lOO@ml Gal-gag110 were added and 
plates were incubated for 2 h at room temperature, solutions were 
removed and plates were washed with PBS containing 0.05% Tween- 
20. The amount of Gal-gag1 0 bound to the MAb lGl2-coated wells 
was determined by assaying its B-galactosidase activity as described 
WI. 
3. RESULTS AND DISCUSSION 
3.1. Inhibition of proteolysis 
In order to assess whether binding of MAb 1612 to 
Gag had an effect on the cleavage of the p17-p24 site 
by HIV-l protease, two types of experiments were con- 
ducted. 
In ELISA-like assays Gal-gag1 10 was bound to (a) 
an immobilized anti-/?-galactosidase monoclonal anti- 
body or(b) immobilized MAb lG12 (Fig. 1). It was then 
challenged with HIV-l protease and the extent of cleav- 
a) b) 
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Fig. 1. Simplified scheme of the ELISA-like experiment showing the 
protection of the p17-p24 cleavage site by MAb lG12. The two cases 
are depicted, i.e. (a) the anti-/?-galactosidase monoclonal antibody or 
(b) MAb lG12 on the solid phase. The detailed procedure is described 
in section 2.2. 
abcde 
Fig. 2. Protection of the p17-p24 cleavage site by MAb lG12, as 
shown by Western blot analysis. Gal-gag110 (100 &ml) was incu- 
bated with MAb lG12 or the anti-/?-galactosidase monoclonal anti- 
body (Promega) before digestion with HIV-l protease. The anti-p-gal 
antibody was also used as primary antibody for detection (see section 
2.2.). Lanes: (a) no HIV-l protease, no antibodies; (b) and (c) both + 
HIV-l protease, + 100 and 4OOj@ml MAb lG12, respectively; (d) + 
HIV-1 protease, + 800 &ml anti-,V-galactosidase antibody; 
(e) + HIV-1 protease, no antibodies. 
age determined in the two cases. From two independent 
experiments, each run in duplicate, the amount of resid- 
ual, uncleaved Gal-gag1 10, expressed as percentage of 
the respective controls (no HIV-l protease), was 
(33 + 4)% for (a) and (94 + 5)% for (b). Hence, Gal- 
gag1 10 was substantially cleaved by the HIV-l protease 
when it was bound by the control antibody. On the 
contrary, binding of MAb lG12 to Gal-gag1 10 pre- 
vented the proteolytic reaction. 
In the second set of experiments all reagents were in 
solution and the HIV-l protease-mediated cleavage of 
Gal-gag1 10 was assayed by immunoblotting. Fig. 2 
shows that the conversion of intact Gal-gag1 10 (about 
130 kDa) into the cleaved product (about 120 kDa) was 
prevented when the protein was preincubated with 
MAb lG12, but not when the control antibody was 
used. This result rules out the possibility that the inter- 
ference in the activity of HIV-l protease in the ELISA 
with MAb lG12 was due to the presence of the solid 
phase. 
Therefore, these experiments indicate that MAb 
lG12 can effectively protect the pl7-p24 cleavage site 
from HIV-l protease-mediated proteolysis. 
3.2. Epitope mapping and specljicity 
To distinguish whether MAb lG12 recognizes a con- 
tiguous sequence or a conformational epitope on the 
Gag polypeptide, different peptides covering the p17- 
p24 boundary region were tested for their ability to 
compete in the binding of Gal-gag1 10 to immobilized 
MAb lG12. In these experiments the amount of bound 
Gal-gag1 10 was quantitated assaying directly its B-ga- 
lactosidase activity. The results shown in Table I, ex- 
pressed as peptide concentrations causing 50% inhibi- 
tion of binding (IC,,), indicate that competition was 
indeed observed. Peptide A, a 15mer made of 7 residues 
from pl7 and 8 residues from ~24, was the most efficient 
competitor. Sequences of the same size, but shifted by 
3 residues to the right (as in peptide B) or to the left (as 
in peptide C) exhibited lower affinity, with a more dra- 
matic effect in the latter case. Peptide D, a 9-mer lacking 
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Table I 
Competition of MAb IGIZ I Gal-gag110 binding 
Peptide Sequence” I& @M)b 
A NQVSQNY*PIVQNIQG 0.18 2 0.04 
B SQNY~P~VQNIQGQ~ 0.70 + 0.15 
C GHSNQVSQNY*PIVQN 12 22 
D SQNY*PIVQN 100 z!z 24 
E SQNY*PIV > 2,000 
’ All sequences include the p17-p24 cleavage site. The scissile peptide 
bond is indicated by an asterisk. 
bMean + S.E.M. Data from three independent experiments, each run 
in duplicate. 
both 3 N-terminal and 3 C-terminal residues of peptide 
A, was still able to bind MAb lG12, even though the 
affinity was in the order of lo4 M. Conversely, the abil- 
ity to compete was completely lost by the 7-mer peptide 
E which instead has been reported to be efkiently rec- 
ognized and cleaved by the HIV-l protease [19]. 
Therefore, these data indicate that MAb lGl2 recog- 
nizes a contiguous sequence on Gag, located around the 
p17-p24 cleavage site, thereby protecting this site from 
the action of HIV-l protease. They also indicate that, 
if compared with the seven-residue minimal sequence 
required by HIV-l protease [19], MAb lGl2 requires, 
for full binding, additional determinants located on 
both sides of that sequence. 
To verify the possibility that MAb lG12 might recog- 
nize other HIV-l protease cleavage sites on Gag, vari- 
ous peptides encompassing different cleavage sites were 
tested in the competition assay. As shown in Table II, 
none of these peptides exhibited any significant affinity 
for MAb 1012. This antibody is therefore specific for 
the p17-p24 cleavage site. 
3.3. conclusions 
In summary, the binding epitope and the specificity 
Table II 
Competition of MAb lGl~G~-gag110 binding 
Peptide Junction Sequence” I% OIM)b 
Gag1255140 p17-p24 NQVSQNY*PIVQNIQG 0.18 + 0.04 
Gag357-371 p24-X GHKARVL*AEAMSQVT > 1,000 
Gag371-385 X-p9 TNTATIM*MQRGNFRN > 1,000 
Gag442456 p9-p6 KGRPGNF*LQSRPEPT z- 1,000 
Po162-76 pls-PR GTVSFNF*PQITLWQR > 100” 
Po1162-176 PR-RT GCTLNF*PISPIETVP > 1,ooo 
a The scissile peptide bond is indicated by an asterisk. 
bMean f S.E.M. Data from three independent experiments, each run 
in duplicate. 
’ Insoluble at higher concentrations. 
Gag 
I ~17 1 p24 1 XI p9 1 p6 1 
1~15 ) PR [ 
--- 
RT --- 
PO1 
of MAb lGl2 have been characterized. The peculiarity 
of its binding site renders this antibody a very interest- 
ing reagent. Indeed, it may be helpful in different areas 
of AIDS research, e.g. detection and quantitation of 
unprocessed vs. processed Gag protein for diagnostic 
purposes, or in vitro studies on the mechanism of proc- 
essing of viral proteins into their mature forms. In this 
area, the possibility to selectively protect a specific HIV- 
1 protease cleavage site is undoubtedly the most inter- 
esting feature of this monoclonal antibody. 
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